Raymond James: ''If Vera is successful with this new plan, it could effectively shorten the theoretical lead Otsuka'
Tweet Send to a Friend
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $78.00 price target on Vera Therapeutics (NASDAQ: VERA)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
